PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $26,403 | $15,222 | $21,891 | $95,587 |
| - Cash | $10,474 | $0 | $25,189 | $38,789 |
| + Debt | $10,917 | $0 | $3,387 | $13,567 |
| Enterprise Value | $26,846 | $15,222 | $89 | $70,365 |
| Revenue | $0 | $0 | – | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$469 | $0 | – | -$1,667 |
| % Margin | – | – | – | – |
| EBITDA | -$11,520 | -$5,486 | – | -$6,495 |
| % Margin | – | – | – | – |
| Net Income | -$11,287 | -$5,690 | – | $5,935 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.72 | 0 | – | 0.19 |
| % Growth | – | – | – | – |
| Operating Cash Flow | -$12,549 | – | – | -$11,100 |
| Capital Expenditures | -$164 | – | – | -$78 |
| Free Cash Flow | -$12,713 | – | – | -$11,178 |